The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
The Commonwealth Games 2026 are scheduled to kick off with the grand opening ceremony in…
National News India Launches Campus Biodiversity Register Initiative For Universities Nationwide India has launched the…
On 22nd July 2026, Honourable President Droupadi Murmu inaugurated a statue of the great Mahatma…
India has commissioned the INS Malvan, it is the second Mahe-class Anti-Submarine Warfare Shallow Water…
Samudra Pradakshina. is the first-ever circumnavigation expedition by women of all three Services of India.…
India has achieved a historic milestone in its railway modernization initiative with the electrification of…